AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38026913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drain
Number of subjects: 196
Study 38027064 — intervention group
Group type: EXPERIMENTAL
Intervention: tremtelectogene empogeditemcel (trem-cel)
Number of subjects: 0
Study 38027064 — intervention group
Group type: EXPERIMENTAL
Intervention: trem-cel
Number of subjects: 0
Study 38027106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg weekly injections
Number of subjects: 44
Study 38027106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 38027217 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism patients
Number of subjects: 161
Study 38027419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2-μg/day fluocinolone acetonide implant (FAi)
Number of subjects: 153
Study 38027419 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 153
Study 38027469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ambroxol (ABX) 1.2 g/day
Number of subjects: 0
Study 38027469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38028143 — intervention group
Group type: EXPERIMENTAL
Intervention: CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan (T-DXd)
Number of subjects: 0
Study 38028143 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab-deruxtecan (T-DXd)
Number of subjects: 0
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (40.4%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery (33.8%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy (CRT) (17.6%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent CRT (9.3%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite radiotherapy (5.0%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone (20.6%)
Number of subjects: 421
Study 38028146 — intervention group
Group type: EXPERIMENTAL
Intervention: Other surgery (20.6%)
Number of subjects: 421
Study 38028163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietician-led dietary intervention
Number of subjects: 156
Study 38028163 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 156
Study 38028272 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic acute intermittent hypoxia (tAIH)
Number of subjects: 0
Study 38028272 — intervention group
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal stimulation-enhanced walking therapy (WALK)
Number of subjects: 0
Study 38028429 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN) device used for acute treatment of migraine, applied for 45 minutes, used on at least 10 days every 28-day month
Number of subjects: 83
Study 38028436 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer prevention information
Number of subjects: 578
Study 38028977 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (9 sessions)
Number of subjects: 65
Study 38028985 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-positive diffuse large B-cell lymphoma treatment
Number of subjects: 0
Study 38028985 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-positive classic Hodgkin lymphoma treatment
Number of subjects: 0
Study 38029215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pugongying granules
Number of subjects: 37
Study 38029215 — intervention group
Group type: COMPARATOR
Intervention: Cefdinir
Number of subjects: 37
Study 38029356 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEPO) - Epoetin alpha 40,000 international units per week administered subcutaneously until hemoglobin (Hb) >11 g/dL and then tapered off.
Number of subjects: 47
Study 38029356 — intervention group
Group type: COMPARATOR
Intervention: AIHA population not treated with rEPO (control group).
Number of subjects: 47
Study 38029357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fol-CHOP (pralatrexate 30 mg/m2 combined with CHOP)
Number of subjects: 33
Study 38029386 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention (online educational module, intraoperative checklist, harmonized surgical techniques)
Number of subjects: 3268
Study 38029386 — intervention group
Group type: EXPERIMENTAL
Intervention: High engagement centres (at least 80% of surgeons completed educational modules)
Number of subjects: 3268
Study 38029386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low engagement hospitals (less than 50% of surgeons completed educational modules)
Number of subjects: 3268
Study 38029625 — intervention group
Group type: EXPERIMENTAL
Intervention: EHS/attributers
Number of subjects: 2040
Study 38029625 — intervention group
Group type: COMPARATOR
Intervention: Non-EHS
Number of subjects: 2040
Study 38029625 — intervention group
Group type: EXPERIMENTAL
Intervention: T-allele of variant rs2302729 of CACNA1C
Number of subjects: 2040
Study 38029689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee Buzzy
Number of subjects: 105
Study 38029689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee Buzzy and puppet
Number of subjects: 105
Study 38029689 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 38029807 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific knockdown of p75NTR
Number of subjects: 0
Study 38029807 — intervention group
Group type: EXPERIMENTAL
Intervention: p75NTR inhibitor LM11A-31
Number of subjects: 0
Study 38029831 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous immune checkpoint inhibitor therapy (ICI)
Number of subjects: 120
Study 38029831 — intervention group
Group type: COMPARATOR
Intervention: Non-ICI
Number of subjects: 120
Study 38030064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 407
Study 38030064 — intervention group
Group type: COMPARATOR
Intervention: Pirfenidone
Number of subjects: 407
Study 38030258 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily
Number of subjects: 388
Study 38030258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 38030303 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg Q2W and spartalizumab 400 mg Q4W)
Number of subjects: 120
Study 38030303 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS793 monotherapy (0.3-1 mg/kg every 3 weeks)
Number of subjects: 120
Study 38030303 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS793 plus spartalizumab (at recommended dose for expansion)
Number of subjects: 120
Study 38030319 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (10 μg/kg subcutaneously once a week for 8 weeks)
Number of subjects: 76
Study 38030318 — intervention group
Group type: EXPERIMENTAL
Intervention: Danicopan plus ravulizumab or eculizumab
Number of subjects: 73
Study 38030318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ravulizumab or eculizumab
Number of subjects: 73
Study 38030318 — intervention group
Group type: EXPERIMENTAL
Intervention: Danicopan
Number of subjects: 73
Study 38030318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 38030558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) gain
Number of subjects: 209
Study 38030558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) loss
Number of subjects: 209
Study 38030558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone loss occurrence
Number of subjects: 209
Study 38030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (76.2% of participants)
Number of subjects: 269
Study 38030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 269
Study 38030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight >30 kg/m
Number of subjects: 269
Study 38030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer joint health
Number of subjects: 269
Study 38030962 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI >30
Number of subjects: 269
Study 38030971 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr)
Number of subjects: 120
Study 38030971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normosaline)
Number of subjects: 120
Study 38030975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified diagnostic strategy combining the YEARS rule and age-adjusted D-dimer threshold
Number of subjects: 1414
Study 38030975 — intervention group
Group type: COMPARATOR
Intervention: Control group using age-adjusted D-dimer threshold only
Number of subjects: 1414
Study 38030988 — intervention group
Group type: EXPERIMENTAL
Intervention: REFRAME intervention (behavioral activation component)
Number of subjects: 81
Study 38030988 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention (psycho-education and mindful monitoring)
Number of subjects: 81
Study 38030991 — intervention group
Group type: EXPERIMENTAL
Intervention: e-visit intervention
Number of subjects: 0
Study 38030991 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 38031004 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication practices during patient-nurse consultations
Number of subjects: 150
Study 38031020 — intervention group
Group type: COMPARATOR
Intervention: Vaginal CO (VagLaser)
Number of subjects: 0
Study 38031088 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule-I group (3 DC injections with 28-day interval)
Number of subjects: 19
Study 38031088 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule-II group (3 DC injections with 7-day interval for first course, then 28-day interval)
Number of subjects: 19
Study 38031088 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue sarcomas (n=13)
Number of subjects: 19
Study 38031088 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosarcomas (n=6)
Number of subjects: 19
Study 38031116 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (Pocc, P0.1, PMI)
Number of subjects: 97
Study 38031116 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (PMI)
Number of subjects: 97
Study 38031116 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (P0.1)
Number of subjects: 97
Study 38031156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds of ≥ 105 steps/min for moderate intensity
Number of subjects: 97
Study 38031156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds of ≥ 115 steps/min or ≥ 120 steps/min for vigorous intensity
Number of subjects: 97
Study 38031156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 105.9 to 112.8 steps/min for relatively-defined moderate intensity
Number of subjects: 97
Study 38031156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 126.1-132.1 steps/min for vigorous intensity
Number of subjects: 97
Study 38031156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 102.0-104.3 steps/min for relatively-defined moderate intensity
Number of subjects: 97
Study 38031180 — intervention group
Group type: EXPERIMENTAL
Intervention: HCS-KY OEND program (naloxone distribution)
Number of subjects: 209
Study 38031180 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone distribution by partner organizations
Number of subjects: 209
Study 38031180 — intervention group
Group type: EXPERIMENTAL
Intervention: County-level naloxone distribution
Number of subjects: 209
Study 38031180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability meeting attendance
Number of subjects: 209
Study 38031584 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of cognitive-behavioral therapy (CBT)
Number of subjects: 45
Study 38031584 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of cognitive-behavioral therapy (CBT)
Number of subjects: 45
Study 38031761 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from uninvolved heavy/light chain pair immunoparesis (uHLC IP) after the first year of maintenance
Number of subjects: 0
Study 38031761 — intervention group
Group type: COMPARATOR
Intervention: Classic immunoparesis (IP)
Number of subjects: 0
Study 38031761 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from uHLC IP after the first year of maintenance
Number of subjects: 0
Study 38031761 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD status and uHLC IP recovery
Number of subjects: 0
Study 38031911 — intervention group
Group type: COMPARATOR
Intervention: Online intervention to address mental health
Number of subjects: 0
Study 38031973 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT System
Number of subjects: 150
Study 38032115 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepWell24 smartphone application
Number of subjects: 87
Study 38032115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study 38032247 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank exercise training
Number of subjects: 0
Study 38032247 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38032260 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38032261 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD) during cardiac rehabilitation (CR)
Number of subjects: 55
Study 38032261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 55
Study 38032277 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant Fiber Extract (PFE)
Number of subjects: 0
Study 38032277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate containing PFE
Number of subjects: 0
Study 38032277 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 38032448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postreperfusion syndrome (PRS)
Number of subjects: 34
Study 38032448 — intervention group
Group type: COMPARATOR
Intervention: Patients without postreperfusion syndrome (non-PRS)
Number of subjects: 34
Study 38032448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PRS
Number of subjects: 34
Study 38032504 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-T index (≥4.9)
Number of subjects: 450
Study 38032504 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-T index (cut-off ≥4.9)
Number of subjects: 450
Study 38032573 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten in addition to standard-of-care medications
Number of subjects: 282
Study 38032573 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to standard-of-care medications
Number of subjects: 282
Study 38032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prior VT/VF
Number of subjects: 714
Study 38032582 — intervention group
Group type: EXPERIMENTAL
Intervention: White women with prior VT/VF
Number of subjects: 714
Study 38032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women with prior VT/VF
Number of subjects: 714
Study 38032621 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided i-CBT
Number of subjects: 1319
Study 38032621 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided i-CBT
Number of subjects: 1319
Study 38032621 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 1319
Study 38032624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hypoglossal nerve stimulation (HGNS) therapy
Number of subjects: 60
Study 38032624 — intervention group
Group type: COMPARATOR
Intervention: Sham hypoglossal nerve stimulation (HGNS) therapy
Number of subjects: 60
Study 38032640 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Auricular Acupuncture (SA)
Number of subjects: 74
Study 38032640 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific Auricular Acupuncture (NSA)
Number of subjects: 74
Study 38032643 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with either parent initiated at birth and continued for the first 6 hours after birth.
Number of subjects: 71
Study 38032643 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator care.
Number of subjects: 71
Study 38032644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 44
Study 38032644 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 44
Study 38032645 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg high-protease pancreatic replacement therapy
Number of subjects: 190
Study 38032645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 38032712 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention for smoking cessation
Number of subjects: 100
Study 38032712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 38032857 — intervention group
Group type: EXPERIMENTAL
Intervention: wMel-infected Aedes aegypti mosquito releases
Number of subjects: 3300000
Study 38032857 — intervention group
Group type: EXPERIMENTAL
Intervention: wMel-treated neighbourhoods
Number of subjects: 3300000
Study 38033143 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment goals
Number of subjects: 0
Study 38033143 — intervention group
Group type: EXPERIMENTAL
Intervention: Life goals
Number of subjects: 0
Study 38033276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Motor Ability Estimator-2 (GMAE-2)
Number of subjects: 53
Study 38033276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Motor Ability Estimator-3 (GMAE-3)
Number of subjects: 53
Study 38033276 — intervention group
Group type: COMPARATOR
Intervention: Gross Motor Ability Estimator-2 (GMAE-2) and Gross Motor Ability Estimator-3 (GMAE-3)
Number of subjects: 53
Study 38033284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg/m
Number of subjects: 30
Study 38033284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg/m
Number of subjects: 30
Study 38033284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 350 mg/m
Number of subjects: 30
Study 38033321 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profiling (GC-MS, CE-MS, and LC-MS)
Number of subjects: 77
Study 38033321 — intervention group
Group type: COMPARATOR
Intervention: Control group of 68 non-cancer individuals
Number of subjects: 77
Study 38033375 — intervention group
Group type: EXPERIMENTAL
Intervention: tablet-based serious game therapy (SGT), 4 months, four 20-min sessions/week
Number of subjects: 150
Study 38033375 — intervention group
Group type: COMPARATOR
Intervention: conventional cognitive exercises, 4 months, four 20-min sessions/week
Number of subjects: 150
Study 38033459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 600 mg/d
Number of subjects: 86
Study 38033459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 38033548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Number of subjects: 1
Study 38033615 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive for NMDAR1-abs (IgM/IgA/IgG)
Number of subjects: 583
Study 38033615 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive with low titers (≤1:100)
Number of subjects: 583
Study 38033615 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive with high titers (>1:100)
Number of subjects: 583
Study 38033615 — intervention group
Group type: COMPARATOR
Intervention: Seronegative for NMDAR1-abs
Number of subjects: 583
Study 38033649 — intervention group
Group type: EXPERIMENTAL
Intervention: EKS
Number of subjects: 128
Study 38033649 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE
Number of subjects: 128
Study 38033649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 38034010 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-MED diet (high polyphenols, low carbohydrates, includes green tea 3-4 cups/day and Wolffia-globosa Mankai plant shake)
Number of subjects: 294
Study 38034010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean (MED) diet (hypocaloric, lower in carbohydrates, includes walnuts 28 g/day)
Number of subjects: 294
Study 38034010 — intervention group
Group type: COMPARATOR
Intervention: Healthy dietary guidelines (HDG)
Number of subjects: 294
Study 38034378 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure variability (BPV)
Number of subjects: 359
Study 38034378 — intervention group
Group type: EXPERIMENTAL
Intervention: High nocturnal heart rate variability (HRV)
Number of subjects: 359
Study 38034378 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function
Number of subjects: 359
Study 38034452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 38034452 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ondansetron)
Number of subjects: 0
Study 38034535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG picosecond laser using fractional micro-lens array (P-MLA)
Number of subjects: 31
Study 38034535 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional 2940-nm Er:YAG laser (AF-Er)
Number of subjects: 31
Study 38034693 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised out-of-bed mobilisation and physical activity training
Number of subjects: 0
Study 38034693 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 0
Study 38034693 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear and logistic regression models
Number of subjects: 0
Study 38034882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 300 mg intravenous every 4 weeks for 12 weeks
Number of subjects: 1162
Study 38034882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 38035037 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 8179
Study 38035037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study 38035038 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 420
Study 38035038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy)
Number of subjects: 420